EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, uniQure NV's enterprise value is $441.73 Mil.
uniQure NV's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $20.20 Mil. Therefore, uniQure NV's EV-to-Revenue for today is 21.87.
The historical rank and industry rank for uniQure NV's EV-to-Revenue or its related term are showing as below:
QURE'
s EV-to-Revenue Range Over the Past 10 Years
Min: -14.66 Med: 12.39 Max: 432.77
Current: 21.87
During the past 13 years, the highest EV-to-Revenue of uniQure NV was 432.77. The lowest was -14.66. And the median was 12.39.
QURE's EV-to-Revenue is ranked worse than 70.65% of 995
companies
in the Biotechnology industry
Industry Median: 7.63
vs QURE: 21.87
As of today (2025-06-26), uniQure NV's stock price is $14.23.
uniQure NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.41. Therefore, uniQure NV's PS Ratio for today is 34.46.
uniQure NV EV-to-Revenue Historical Data
The historical data trend for uniQure NV's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of uniQure NV's EV-to-Revenue
For the Biotechnology subindustry, uniQure NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where uniQure NV's EV-to-Revenue falls into.
uniQure NV's current Enterprise Value is $441.73 Mil.
uniQure NV's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV's share price for today is $14.23.
uniQure NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.41.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of uniQure NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
QURE has been successfully added to your 